Zeldox and Zyprexa IM formulations
Executive Summary
FDA Psychopharmacologic Drugs Advisory Committee will review intramuscular formulations of Lilly's Zyprexa (olanzapine) and Pfizer's Zeldox (ziprasidone) for use in schizophrenia during February meeting. Zyprexa, which is already marketed in an oral formulation, will be reviewed on Feb. 14. Zeldox, which is "approvable" at FDA in an oral formulation, will be reviewed on the second day. The meeting will take place at the Holiday Inn-Gaithersburg, Md., beginning at 8 a.m. both days
You may also be interested in...
Pfizer Zeldox
European mutual recognition procedure delayed for antipsychotic ziprasidone, company said Dec. 21. Pfizer will supplement the European filing with data from its NDA. Zeldox is "approvable" at FDA in an oral formulation, and a FDA advisory committee will review the intramuscular formulation Feb. 15 (1"The Pink Sheet" Dec. 11, 2000, In Brief)
Pfizer Zeldox
European mutual recognition procedure delayed for antipsychotic ziprasidone, company said Dec. 21. Pfizer will supplement the European filing with data from its NDA. Zeldox is "approvable" at FDA in an oral formulation, and a FDA advisory committee will review the intramuscular formulation Feb. 15 (1"The Pink Sheet" Dec. 11, 2000, In Brief)
Pfizer Neurontin Neuropathic Pain NDA Planned; Relpax Awaits New Study
Pfizer is preparing an NDA supplement for Neurontin that could allow open marketing of gabapentin for neuropathic pain indications.